Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients†‡
Open Access
- 15 April 2005
- journal article
- viral hepatitis
- Published by Wolters Kluwer Health in Hepatology
- Vol. 41 (5) , 995-1003
- https://doi.org/10.1002/hep.20664
Abstract
The factors and mechanisms implicated in the development of hepatitis C virus (HCV)‐related steatosis are unknown. Hyperhomocysteinemia causes steatosis, and the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism induces hyperhomocysteinemia. We investigated the role of these factors in the development of HCV‐related steatosis and in the progression of chronic hepatitis C (CHC). One hundred sixteen CHC patients were evaluated for HAI, fibrosis and steatosis grades, body mass index, HCV genotypes, HCV RNA levels, homocysteinemia, and the MTHFR C677T polymorphism. Hyperhomocysteinemia was associated with the TT genotype of MTHFR (r = 0.367; P = .001). Median values of homocysteine in the CC, CT, and TT genotypes of the MTHFR gene were 9.3, 12.2, and 18.6 μmol/L, respectively (P = .006). Steatosis correlated with the MTHFR polymorphism, homocysteinemia, HAI and fibrosis. Steatosis above 20% was significantly associated with fibrosis. Prevalence and high grade (>20%) of steatosis were 41% and 11% in CC, 61% and 49% in CT, and 79% and 64% in TT, respectively (P = .01). Relative risk of developing high levels of steatosis was 20 times higher for TT genotypes than CC genotypes. According to multivariate analysis, steatosis was independently associated with hyperhomocysteinemia (OR = 7.1), HAI (OR = 3.8), liver fibrosis (OR = 4.0), and HCV genotype 3 (OR = 4.6). On univariate analysis, fibrosis was associated with age, steatosis, MTHFR, homocysteinemia and HAI; however, on multivariate analysis, liver fibrosis was independently associated with age (P = .03), HAI (P = .0001), and steatosis (P = .007). In conclusion, a genetic background such as the MTHFR C677T polymorphism responsible for hyperhomocysteinemia plays a role in the development of higher degree of steatosis, which in turn accelerates the progression of liver fibrosis in CHC. (HEPATOLOGY 2005.)Keywords
Funding Information
- Ministero dell'Istruzione, Università e Ricerca Scientifica, Rome, Italy (2002062883-005)
This publication has 33 references indexed in Scilit:
- Effect of Treatment With Peginterferon or Interferon Alfa–2B and Ribavirin on Steatosis in Patients Infected With Hepatitis CHepatology, 2003
- Homocysteine‐betaine interactions in a murine model of 5,10‐methylenetetrahydrofolate reductase deficiencyThe FASEB Journal, 2003
- Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic responseHepatology, 2002
- Increased plasma homocysteine in liver cirrhosisHepatology Research, 2001
- Fibrosis in Chronic Hepatitis C Correlates Significantly With Body Mass Index and SteatosisHepatology, 1999
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Classification of chronic hepatitis: Diagnosis, grading and stagingHepatology, 1994
- Classification of chronic viral hepatitis: a need for reassessmentPublished by Elsevier ,1991
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981
- Homocystinuria due to cystathionine synthase deficiency: Enzymatic and ultrastructural studiesThe Journal of Pediatrics, 1974